Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Antisense battles small molecule for slice of rare lipid disorder market

Nature Biotechnology volume 31, pages 179–180 (2013)Cite this article

Subjects

“Kynamro marks the first approval of a systemically administered antisense drug in humans and has certainly validated Isis' [antisense] platform,” says Nicholas Bishop, a biotech analyst at Cowen and Company in New York. The approval also opens the door to other antisense drugs. “Certainly, the approval of Kynamro for a chronic indication reflects a comfort level with the FDA for antisense in general,” says Stanley Crooke, CEO of Isis.

Your institute does not have access to this article

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

Buy

All prices are NET prices.

Author information

Authors and Affiliations

  1. Berlin

    Gunjan Sinha

Authors
  1. Gunjan Sinha
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Sinha, G. Antisense battles small molecule for slice of rare lipid disorder market. Nat Biotechnol 31, 179–180 (2013). https://doi.org/10.1038/nbt0313-179

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0313-179

Further reading

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing